Cardiol Therapeutics (TSE:CRDL) Shares Down 5% – What’s Next?

Shares of Cardiol Therapeutics Inc. (TSE:CRDL) fell 5% on Tuesday . The stock traded as low as C$1.51 and last traded at C$1.52. 86,322 shares changed hands during mid-day trading, an increase of 35% from the average session volume of 64,026 shares. The stock had previously closed at C$1.60.

Cardiol Therapeutics Trading Up 2.1 %

The company has a quick ratio of 6.84, a current ratio of 2.49 and a debt-to-equity ratio of 1.59. The company has a market cap of C$120.32 million, a price-to-earnings ratio of -2.85 and a beta of 0.70. The firm has a 50 day moving average price of C$1.76 and a two-hundred day moving average price of C$2.17.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.